Surrozen, Inc.
$29.16-13.4%YTD+46.4%1Y+186.6%
Price updated 4m ago
On X
The complete picture of $SRZN on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.
0X posts · last 7 days
No mention history yetWhat it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $SRZN.
Biotechnology
No material change from last week — mRNA oncology platform remains the structural driver; MRNA's personalized cancer vaccine (melanoma Phase 3 Oct readout) has extended a 137% monthly run. IBB +42% T12M reflects broad RNA-medicine and gene-editing multiple re-rating; GLP-1 pipeline names (ALT, VKTX, KLRA) are the secondary near-term catalyst cohort.
Top industry ETF
$IBBiShares Biotechnology ETF
+23.3%YTD
+47.7%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-0.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-40.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-385%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-13.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
21.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
188%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
99.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
-0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.41$-1.29+68.2%
Q1 2026May 6, 2026$-11.65$-1.39-738.1%
Q4 2025Mar 23, 2026$-19.13$-1.29-1385.8%
Q3 2025Nov 7, 2025$-8.36$-1.17-614.5%
Next earningsFri, Nov 6·consensus EPS $-1.10
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$5.0M+408.6%100%-207%$2.75$-7.4M
Q1 FY26$5.0M+408.6%98.7%-209%$-11.65$-12.6M
Q4 FY25$528K-19.4%100%-2394%$-23.87$-5.9M
Q3 FY25$983K-90.2%100%-1107%$-8.36$-9.1M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$10.7M$10.2M – $11.6M-$7.01-$7.85 – -$6.414
FY27$1.5M$1.4M – $1.6M-$3.61-$4.32 – -$2.945
FY28$869K$828K – $938K-$3.65-$5.28 – -$2.504
FY29$869K$828K – $938K-$3.89-$4.30 – -$3.652
FY30$2.0M$1.9M – $2.2M-$4.31-$4.75 – -$4.042
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.60.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.91%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+55.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+38.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatTiny float · 3.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today351.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.565-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Surrozen Gains Momentum as FDA Submission Opens Path for Lead TherapySurrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSurrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular EdemaSurrozen to Present at Upcoming Healthcare Investor ConferencesSurrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $SRZN on X in the last 7 days.